Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165487 · ClinicalTrials.gov registry record
Comparison of the Breast Tumor Microenvironment
A clinical trial of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast, sponsored by Columbia University.
- Active
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT03165487: Active study of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast, sponsored by Columbia University.
NCT03165487 is a study of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 14 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03165487, a study of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care.
Primary Outcome
This outcome measure is designed to measure the amount of TILs in newly diagnosed luminal A and Triple Negative Breast Cancer (TNBC) tumors. The mean percent change in TILS in tumor tissue from initial core biopsy samples will be compared with pathology samples from definitive surgery after IORT between the two different breast cancer sub-types.
Conditions Studied
Interventions
- OTHER Blood sample collection
- OTHER Breast tissue collection
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2027-12-01 |
What the registry record for NCT03165487 still lists
NCT03165487 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood sample collection is the first listed.
NCT03165487 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03165487 about?
NCT03165487 is a clinical study titled "Comparison of the Breast Tumor Microenvironment". The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative bre...
What is the current status of trial NCT03165487?
This trial is currently active not recruiting. The enrollment target is 14 participants. The study started on 2017-09-28. Estimated completion is 2027-12-01.
What conditions does trial NCT03165487 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast.
What interventions are being tested in trial NCT03165487?
The interventions under investigation include: Blood sample collection (OTHER), Breast tissue collection (OTHER).
Who is sponsoring clinical trial NCT03165487?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03165487 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03165487's enrollment target sits among peer trials
14 110th of 118 higher than 9 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy